Showing results (21-30 of 80) with videos related to
Sort By:
Pageof 8
Gynecologic Oncology|September 24, 2020
Homologous recombination deficiency real-time clinical assays, ready or not?Katherine Fuh, Mary Mullen, Barbara Blachut, et al.Gynecologic Oncology|October 28, 2025
The impact of romiplostim use for chemotherapy induced thrombocytopenia on immediate and long-term outcomes in gynecologic malignanciesSurabhi Tewari, Ellery Koelker-Wolfe, Andrea Pelletier, et al.Gynecologic Oncology|April 24, 2025
A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancerKelly J Fitzgerald, Panagiotis Konstantinopoulos, Ursula Matulonis, et al.Gynecologic Oncology|December 22, 2014
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinomaUrsula Matulonis, Ignace Vergote, Floor Backes, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 20, 2020
Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assaysCarrie L Robinson, Beth T Harrison, Azra H Ligon, et al.Journal of the Society for Integrative Oncology|February 21, 2007
Acupuncture for chemotherapy-induced leukopenia: exploratory meta-analysis of randomized controlled trialsWeidong Lu, David Hu, Elizabeth Dean-Clower, et al.Gynecologic Oncology|December 25, 2012
Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancerKanokpis Townamchai, Ross Berkowitz, Mandar Bhagwat, et al.Oncoimmunology|May 4, 2016
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse modelDe-Kuan Chang, Eric Peterson, Jiusong Sun, et al.Gynecologic Oncology|November 9, 2013
A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancerAkila N Viswanathan, Hang Lee, Ross Berkowitz, et al.Gynecologic Oncology|August 14, 2012
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinomaSusana M Campos, Richard T Penson, Ursula Matulonis, et al.Pageof 8